INS and type 2 diabetes mellitus: Conversely, antagomiR-103 and -107 treatment in obese mice improved glucose tolerance and insulin sensitivity in liver and adipose tissue, and it rescued β-oxidation pathway genes like Cpt1. 13Currently, a clinical phase I or IIa trial is ongoing, which applies antagomiR-103 and -107 in patients with steatohepatitis and type 2 diabetes.